MBRX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Moleculin Biotech Inc

NASDAQ | MBRX

4.14

USD

$0.00

(

0.00%

)

At Close (As of Dec 17, 2025)

$22.47M

Market Cap

-

P/E Ratio

-3.74

EPS

$69.50

52 Week High

$3.63

52 Week Low

HEALTHCARE

Sector

MBRX Chart

Recent Chart
Price Action

MBRX Technicals

Tags:

MBRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$126K
Total Revenue $0
Cost Of Revenue $126K
Costof Goods And Services Sold $126K
Operating Income -$27M
Selling General And Administrative $8.8M
Research And Development $18M
Operating Expenses $27M
Investment Income Net -
Net Interest Income $550K
Interest Income $550K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $126K
Income Before Tax -$22M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$27M
Net Income -$22M

Revenue & Profitability

Earnings Performance

MBRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $17M
Total Current Assets $5.2M
Cash And Cash Equivalents At Carrying Value $4.3M
Cash And Short Term Investments $4.3M
Inventory -
Current Net Receivables $20K
Total Non Current Assets $12M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $11M
Intangible Assets Excluding Goodwill $11M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $916K
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $5.4M
Current Accounts Payable $2M
Deferred Revenue -
Current Debt -
Short Term Debt $120K
Total Non Current Liabilities $5.6M
Capital Lease Obligations $478K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $478K
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $6M
Treasury Stock -
Retained Earnings -$153M
Common Stock $3K
Common Stock Shares Outstanding $138K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $126K
Capital Expenditures $13K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$13K
Cashflow From Financing $4.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$22M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$126K
Total Revenue $0
Cost Of Revenue $126K
Costof Goods And Services Sold $126K
Operating Income -$27M
Selling General And Administrative $8.8M
Research And Development $18M
Operating Expenses $27M
Investment Income Net -
Net Interest Income $550K
Interest Income $550K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $126K
Income Before Tax -$22M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$27M
Net Income -$22M

MBRX News

MBRX Profile

Moleculin Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, dedicated to the advancement of innovative therapies for cancer and viral infections. Utilizing proprietary technology, the company is developing a diverse pipeline of drug candidates designed to target resistant tumors and address significant unmet medical needs in oncology. With a strong commitment to scientific innovation and therapeutic breakthroughs, Moleculin Biotech is well-positioned to shape the future of cancer treatment and make substantial contributions to the field of oncology.

LPTX
+368.57%
$2.05
ATPC
+56.44%
$0.14
VYNE
+48.99%
$0.60
NVDA
-3.81%
$170.94
YCBD
+58.74%
$2.27
PAVS
-13.47%
$0.01
DRCT
+10.45%
$0.07
YGMZ
-61.42%
$0.02
IRBT
+0.23%
$0.76
TSLA
-4.61%
$467.26
CGC
+4.91%
$1.92
WOK
+4.25%
$0.05
PLUG
-5.67%
$2.16
AVGO
-4.47%
$326.02
VTGN
-80.25%
$0.86
WBD
-2.38%
$28.21
AXDX
-61.36%
$0.03
ASST
-4.60%
$0.82
RXRX
+11.42%
$4.68
RZLV
-19.19%
$2.40
PFE
-1.91%
$25.04
ONDS
-8.89%
$7.37
F
-2.63%
$13.31
AAL
-3.00%
$15.51
PLTD
+5.77%
$6.68
BMNR
-6.59%
$29.32
SNAP
+1.76%
$7.50
INTC
-3.37%
$36.05
BMNU
-13.05%
$5.73
ADAP
-15.14%
$0.05
BITF
-4.52%
$2.32
NFLX
+0.23%
$94.79
PLTR
-5.57%
$177.29
SOFI
-4.92%
$25.27
AAPL
-1.00%
$271.84
ORCL
-5.40%
$178.46
LAZR
-27.79%
$0.22
CIFR
-4.00%
$14.39
CRWV
-7.12%
$64.55
MARA
-7.10%
$9.93
ACHR
-4.65%
$7.58
SRXH
-7.61%
$0.34
WULF
-10.93%
$11.57
AMZN
-0.57%
$221.27
GOOGL
-3.21%
$296.72
SOND
-23.45%
$0.12
DNN
-4.61%
$2.48
BYND
-4.54%
$1.05
RMBL
+60.50%
$3.21
ADTX
+22.53%
$1.74
LNW
-3.71%
$86.22
GRAB
-1.61%
$4.87
PCSA
+122.29%
$6.68
T
+1.20%
$24.36
ADD
-25.47%
$0.05
KVUE
+0.17%
$17.28
BBD
-1.19%
$3.31
HOOD
-3.01%
$115.80
MU
-3.00%
$225.52
RIG
+2.86%
$3.95
IVP
-5.80%
$0.04
SRM
+53.27%
$10.30
BAC
-0.47%
$54.55
RGTI
-6.21%
$22.47
IREN
-7.67%
$33.78
RIVN
-1.50%
$17.63
VHAI
0.00%
$0.00
AMD
-5.28%
$198.11
HPE
-1.15%
$24.02
NAKA
-4.14%
$0.36
TLRY
-7.60%
$12.88
OCG
-4.24%
$0.14
ITUB
-2.08%
$7.04
BTBT
-6.19%
$1.97
QBTS
-6.73%
$23.80
BTG
+0.43%
$4.57
APLD
-9.24%
$22.00
CPNG
-2.02%
$22.72
VICI
+1.87%
$28.39
UBER
-2.19%
$79.14
CMG
+3.75%
$37.00
GOOG
-3.14%
$298.06
CLSK
-3.20%
$11.48
VIVK
-14.57%
$0.05
NIO
-3.37%
$4.86
AG
-0.12%
$16.38
VALE
+0.55%
$12.79
PBR
-0.16%
$11.77
HBAN
+0.68%
$17.75
AKAN
-0.67%
$0.74
RKLB
-2.75%
$53.96
AMC
-5.69%
$1.82
AFMD
-34.94%
$0.18
MSFT
-0.05%
$476.12
PCG
+2.68%
$15.68
TWO
+12.10%
$11.11
ABEV
-1.37%
$2.51
SMR
-8.06%
$15.74
TE
-0.36%
$5.42
KOS
-5.21%
$0.91
LPTX
+368.57%
$2.05
ATPC
+56.44%
$0.14
VYNE
+48.99%
$0.60
NVDA
-3.81%
$170.94
YCBD
+58.74%
$2.27
PAVS
-13.47%
$0.01
DRCT
+10.45%
$0.07
YGMZ
-61.42%
$0.02
IRBT
+0.23%
$0.76
TSLA
-4.61%
$467.26
CGC
+4.91%
$1.92
WOK
+4.25%
$0.05
PLUG
-5.67%
$2.16
AVGO
-4.47%
$326.02
VTGN
-80.25%
$0.86
WBD
-2.38%
$28.21
AXDX
-61.36%
$0.03
ASST
-4.60%
$0.82
RXRX
+11.42%
$4.68
RZLV
-19.19%
$2.40
PFE
-1.91%
$25.04
ONDS
-8.89%
$7.37
F
-2.63%
$13.31
AAL
-3.00%
$15.51
PLTD
+5.77%
$6.68
BMNR
-6.59%
$29.32
SNAP
+1.76%
$7.50
INTC
-3.37%
$36.05
BMNU
-13.05%
$5.73
ADAP
-15.14%
$0.05
BITF
-4.52%
$2.32
NFLX
+0.23%
$94.79
PLTR
-5.57%
$177.29
SOFI
-4.92%
$25.27
AAPL
-1.00%
$271.84
ORCL
-5.40%
$178.46
LAZR
-27.79%
$0.22
CIFR
-4.00%
$14.39
CRWV
-7.12%
$64.55
MARA
-7.10%
$9.93
ACHR
-4.65%
$7.58
SRXH
-7.61%
$0.34
WULF
-10.93%
$11.57
AMZN
-0.57%
$221.27
GOOGL
-3.21%
$296.72
SOND
-23.45%
$0.12
DNN
-4.61%
$2.48
BYND
-4.54%
$1.05
RMBL
+60.50%
$3.21
ADTX
+22.53%
$1.74
LNW
-3.71%
$86.22
GRAB
-1.61%
$4.87
PCSA
+122.29%
$6.68
T
+1.20%
$24.36
ADD
-25.47%
$0.05
KVUE
+0.17%
$17.28
BBD
-1.19%
$3.31
HOOD
-3.01%
$115.80
MU
-3.00%
$225.52
RIG
+2.86%
$3.95
IVP
-5.80%
$0.04
SRM
+53.27%
$10.30
BAC
-0.47%
$54.55
RGTI
-6.21%
$22.47
IREN
-7.67%
$33.78
RIVN
-1.50%
$17.63
VHAI
0.00%
$0.00
AMD
-5.28%
$198.11
HPE
-1.15%
$24.02
NAKA
-4.14%
$0.36
TLRY
-7.60%
$12.88
OCG
-4.24%
$0.14
ITUB
-2.08%
$7.04
BTBT
-6.19%
$1.97
QBTS
-6.73%
$23.80
BTG
+0.43%
$4.57
APLD
-9.24%
$22.00
CPNG
-2.02%
$22.72
VICI
+1.87%
$28.39
UBER
-2.19%
$79.14
CMG
+3.75%
$37.00
GOOG
-3.14%
$298.06
CLSK
-3.20%
$11.48
VIVK
-14.57%
$0.05
NIO
-3.37%
$4.86
AG
-0.12%
$16.38
VALE
+0.55%
$12.79
PBR
-0.16%
$11.77
HBAN
+0.68%
$17.75
AKAN
-0.67%
$0.74
RKLB
-2.75%
$53.96
AMC
-5.69%
$1.82
AFMD
-34.94%
$0.18
MSFT
-0.05%
$476.12
PCG
+2.68%
$15.68
TWO
+12.10%
$11.11
ABEV
-1.37%
$2.51
SMR
-8.06%
$15.74
TE
-0.36%
$5.42
KOS
-5.21%
$0.91
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.